Insights

2026 Future Healthcare and Medicine Conference · Panlin Capital Post-investment Empowerment Seminar centers on reassessing high-quality assets within China’s innovative medical sector. At the 2026 AACR Annual Meeting, 104 Chinese pharmaceutical enterprises showcased over 250 research achievements, breaking the dominance of multinational industry giants. In 2025, China granted approval to 76 innovative drugs and 76 innovative medical devices. As of 2026, the total value of BD transactions involving domestic innovative drugs has surpassed $49 billion. China’s medical innovation industry is evolving from a fast follower into a systematic innovator. Multinational corporations have fundamentally adjusted their evaluation criteria for Chinese medical innovative assets and shifted focus to strategic industrial layout. Li Yuhui, Founding Managing Partner of Panlin Capital, stated that revaluing premium innovative medical assets in China has become a core industry topic.

DVT most commonly occurs in the lower extremities, and its major adverse consequences are pulmonary thromboembolism (PE) and post-thrombotic syndrome (PTS). Acute PE has a mortality rate as high as 20%–30%, representing an extremely high risk of fatality. If acute DVT is not diagnosed and treated in a timely manner, it can progress to chronic DVT, with 30%–50% of patients developing PTS within two years。

20n Bio's platform enables rapid discovery of high-affinity, high-selectivity cyclic peptide binders against a wide range of disease-related targets from ultra-large cyclic peptide libraries. The Company has demonstrated de novo cyclic peptide discovery capabilities across multiple targets; several molecules discovered through the platform have generated in vivo data through out-licensed programs, further supporting the translational potential of the platform's discovered molecules.

Forlong Biotechnology has established a globally leading integrated synthetic immunology technology system, comprising four proprietary core technology platforms: the Fbody® long-acting platform, the Syntokine® novel synthetic cytokine platform, the Fc engineering platform, and the AI-powered macromolecule intelligent discovery platform. These four platforms enable multi-dimensional optimization of protein therapeutics, particularly cytokines, with the goal of overcoming the developability challenges of cytokines and developing novel biologics with high safety profiles and excellent efficacy.

At the recently held 2026 Future Healthcare and Medicine Conference in Shanghai, leading executives and investors from China and the global healthcare industry gathered to discuss the future of medical and pharmaceutical innovation. The agenda covered not only technology-driven trends such as AI-enabled innovation and end-to-end digitalization, but also a critical challenge facing Chinese healthcare companies as they expand globally: how to move beyond “product expansion” and achieve “true brand expansion”.

By the end of 2026, Full-Life expects to have three differentiated clinical-stage programs, all originating from its proprietary UniRDC™ discovery platform. In addition, the funds will support the initiation of GMP-grade actinium-225 (225Ac) isotope production at the Company's advanced manufacturing facility in Belgium. The ability to control isotope supply and production in-house represents a key strategic advantage for Full-Life as it accelerates clinical development of its radiotherapeutics.